The Cochlear (ASX:COH) share price is down 8% in 4 weeks. Is it a buy?

Is it time to buy this healthcare share?

The Cochlear Limited (ASX: COH) share price has been a positive performer on Wednesday.

In afternoon trade, the hearing solutions company's shares are up over 2% to $235.39.

This means the Cochlear share price is now up 24% since the start of the year. This is despite its shares falling 8% over the last four weeks.

Person thinking with another person's hand drawing a question mark on a blackboard in the background.

Image source: Getty Images

Is the Cochlear share price good value?

One top broker is likely to see the recent pullback in the Cochlear share price as a buying opportunity for investors.

In response to the company's full year results last month, the team at Macquarie Group Ltd (ASX: MQG) retained their outperform rating but trimmed their price target on its shares by 3% to $256.00.

Based on the current Cochlear share price, this suggests there's still approximately 9% upside over the next 12 months.

What did the broker say?

According to the note, Macquarie was pleased with the company's performance in FY 2021.

For the 12 months ended 30 June, Cochlear reported a 10% increase in sales revenue to $1,493.3 million and a 54% jump in underlying net profit to $236.7 million. The latter was in line with Macquarie's expectations and also the company's guidance of $225 million to $245 million.

However, one thing that did fall short was the company's guidance for FY 2022. Cochlear is expecting net profit growth of 12% to 20% for the year ahead.

Macquarie was expecting stronger growth, which led to its analysts revising its earnings per share estimate for FY 2022 down by approximately 11%.

Nevertheless, the broker remains positive on the company's outlook and the Cochlear share price. This is due to its belief that the company is positively leveraged to a post-pandemic recovery in activity levels.

Macquarie also noted recently that its survey of US based audiologists was very favourable. Its survey found that Cochlear's products were the highest rated in the industry and met key criteria for both adult and paediatric patients. As a result, the company is expected to grow its market share over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

three young children weariing business suits, helmets and old fashioned aviator goggles wear aeroplane wings on their backs and jump with one arm outstretched into the air in an arid, sandy landscape.
Broker Notes

5 ASX 200 stocks analysts have upgraded this week

Brokers have increased their ratings on PLS Group, Mineral Resources, Ampol, and other stocks. 

Read more »

Children skipping and jumping up a hill.
Broker Notes

3 ASX small-cap shares with 48% to 128% upside ahead: Morgans

The ASX Small Ords Index has collapsed 18% in 2026 and this broker sees buying opportunities.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Broker Notes

6 ASX shares hit by broker downgrades this week

Brokers reduced their ratings on South32, Boss Energy, Sonic Healthcare, and other stocks.

Read more »

A man leaps from a stack of gold coins to the next, each one higher than the last.
Broker Notes

3 ASX shares tipped by brokers to return 41% to 85% in the next 12 months

These ASX shares are expected to be among the top performers next year.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, and holding a mobile phone in his other hand.
Broker Notes

Buy, hold, sell: Siteminder, Bluescope Steel, Evolution shares

Experts share their thoughts and ratings on three ASX stocks.

Read more »

Work colleagues discussing finance charts and graphs on a laptop computer and tablet in their office.
Broker Notes

Buy, hold, sell: Reece, Fortescue, Electro Optic Systems shares

Experts reveal their ratings on 3 ASX 200 shares in the industrials and mining segments. 

Read more »

Happy businessman fist pumping while looking at a tablet.
Broker Notes

Could Paladin Energy shares return 90% in 12 months?

This uranium miner's shares could be undervalued according to one leading broker.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Broker Notes

Brokers tip these 2 ASX shares to jump 46% and 62%

Both these ASX shares are trading lower on Wednesday.

Read more »